

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.0	30.09.2023	785872-00016	Date of first issue: 28.06.2016

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Orbifloxacin Liquid Formulation

Manufacturer or supplier's details

Company : MSD

Address : Briahnager - Off Pune Nagar Road
Wagholi - Pune - India 412 207

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Reproductive toxicity : Category 2

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Eye)

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.
H373 May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Precautionary statements : **Prevention:**
P203 Obtain, read and follow all safety instructions before use.

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version 4.0 Revision Date: 30.09.2023 SDS Number: 785872-00016 Date of last issue: 04.04.2023
Date of first issue: 28.06.2016

P260 Do not breathe mist or vapours.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P318 IF exposed or concerned, get medical advice.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Orbifloxacin	113617-63-3	$\geq 3 - < 5$
Silicon dioxide	7631-86-9	$\geq 1 - < 5$
Lactic acid	50-21-5	$\geq 1 - < 3$
Sodium hydroxide	1310-73-2	$\geq 1 - < 2$

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.0	30.09.2023	785872-00016	Date of first issue: 28.06.2016

Notes to physician : when the potential for exposure exists (see section 8).
: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version 4.0 Revision Date: 30.09.2023 SDS Number: 785872-00016 Date of last issue: 04.04.2023
Date of first issue: 28.06.2016

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Orbifloxacin	113617-63-3	TWA	0.2 mg/m ³ (OEB 2)	Internal
Silicon dioxide	7631-86-9	TWA (Total dust)	10 mg/m ³ (Silica)	IN OEL
Sodium hydroxide	1310-73-2	CEIL	2 mg/m ³	IN OEL
		C	2 mg/m ³	ACGIH

- Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Combined particulates and organic vapour type
- Hand protection : Chemical-resistant gloves
- Material
- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.0	30.09.2023	785872-00016	Date of first issue: 28.06.2016

Skin and body protection	: aerosols. Work uniform or laboratory coat.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: suspension
Colour	: light brown
Odour	: odourless
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available
Relative vapour density	: No data available
Relative density	: No data available
Density	: No data available
Solubility(ies) Water solubility	: No data available

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.0	30.09.2023	785872-00016	Date of first issue: 28.06.2016

Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
Acute inhalation toxicity	:	Acute toxicity estimate: > 10 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: Calculation method

Components:

Orbifloxacin:

Acute oral toxicity	:	LD50 (Rat): > 3,000 mg/kg
---------------------	---	---------------------------

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.0	30.09.2023	785872-00016	Date of first issue: 28.06.2016

Remarks: No mortality observed at this dose.

LD50 (Mouse): > 2,000 mg/kg

Remarks: No mortality observed at this dose.

LD50 (Dog): > 600 mg/kg

Symptoms: Vomiting

Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 200 mg/kg
Application Route: Intramuscular

LD50 (Mouse): 500 mg/kg
Application Route: Intramuscular

LD50 (Rat): 233 mg/kg
Application Route: Intravenous

LD50 (Mouse): 250 mg/kg
Application Route: Intravenous

Silicon dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): > 2.08 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Lactic acid:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Assessment: Corrosive to the respiratory tract.
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity
Remarks: Based on data from similar materials

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.0	30.09.2023	785872-00016	Date of first issue: 28.06.2016

Sodium hydroxide:

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Skin corrosion/irritation

Not classified based on available information.

Product:

Species : Rabbit
Result : No skin irritation

Components:

Orbifloxacin:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Silicon dioxide:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Lactic acid:

Species : Rabbit
Method : OECD Test Guideline 404
Result : Corrosive after 1 to 4 hours of exposure
Remarks : Based on data from similar materials

Sodium hydroxide:

Result : Corrosive after 3 minutes or less of exposure

Serious eye damage/eye irritation

Not classified based on available information.

Product:

Species : Rabbit
Result : Mild eye irritation

Components:

Orbifloxacin:

Species : Rabbit
Method : Draize Test
Result : Mild eye irritation

Silicon dioxide:

Species : Rabbit
Method : OECD Test Guideline 405
Result : No eye irritation

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.0	30.09.2023	785872-00016	Date of first issue: 28.06.2016

Lactic acid:

Species	: Chicken eye
Remarks	: Based on data from similar materials

Result	: Irreversible effects on the eye
--------	-----------------------------------

Sodium hydroxide:

Result	: Irreversible effects on the eye
Remarks	: Based on skin corrosivity.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Product:

Test Type	: Magnusson-Kligman-Test
Exposure routes	: Dermal
Species	: Guinea pig
Result	: Not a skin sensitizer.

Components:

Orbifloxacin:

Test Type	: Maximisation Test
Exposure routes	: Dermal
Species	: Guinea pig
Result	: Not a skin sensitizer.

Lactic acid:

Test Type	: Buehler Test
Exposure routes	: Skin contact
Species	: Guinea pig
Result	: negative
Remarks	: Based on data from similar materials

Sodium hydroxide:

Test Type	: Human repeat insult patch test (HRIPT)
Exposure routes	: Skin contact
Result	: negative

Germ cell mutagenicity

Not classified based on available information.

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version
4.0

Revision Date:
30.09.2023

SDS Number:
785872-00016

Date of last issue: 04.04.2023
Date of first issue: 28.06.2016

Components:

Orbifloxacin:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: equivocal Test Type: Mouse Lymphoma Result: positive Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Intraperitoneal injection Result: negative Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

Silicon dioxide:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative

Lactic acid:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative Remarks: Based on data from similar materials Test Type: In vitro mammalian cell gene mutation test Method: OECD Test Guideline 476 Result: negative Remarks: Based on data from similar materials Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative
-----------------------	--

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.0	30.09.2023	785872-00016	Date of first issue: 28.06.2016

Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

Orbifloxacin:

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 200 mg/kg body weight
Result	: negative

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 200 mg/kg body weight
Result	: negative

Silicon dioxide:

Species	: Rat
Application Route	: Ingestion
Exposure time	: 103 weeks
Result	: negative

Lactic acid:

Species	: Rat
Application Route	: Ingestion
Exposure time	: 2 Years
Result	: negative
Remarks	: Based on data from similar materials

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Orbifloxacin:

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity - Parent: NOAEL: 50 mg/kg body weight Early Embryonic Development: NOAEL: 50 mg/kg body weight Result: No adverse effects
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.0	30.09.2023	785872-00016	Date of first issue: 28.06.2016

Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Oral

General Toxicity Maternal: NOAEL: 20 mg/kg body weight

Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight

Result: No effects on early embryonic development, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain

Test Type: Development

Species: Dog

Application Route: Oral

Developmental Toxicity: LOAEL: 2.5 mg/kg body weight

Result: Effects on postnatal development, Skeletal malformations

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

Silicon dioxide:

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

Lactic acid:

Effects on foetal development : Test Type: Embryo-foetal development
Species: Mouse
Application Route: Ingestion
Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Product:

Target Organs : Eye
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Product:

Species : Dog
NOAEL : 22.5 mg/kg

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.0	30.09.2023	785872-00016	Date of first issue: 28.06.2016

LOAEL	:	37.5 mg/kg
Application Route	:	Oral
Exposure time	:	30 Days
Symptoms	:	Gastrointestinal disturbance
Species	:	Dog
LOAEL	:	75 mg/kg
Application Route	:	Oral
Exposure time	:	10 Days
Symptoms	:	Salivation, Gastrointestinal disturbance, Vomiting
Species	:	Cat
LOAEL	:	45 mg/kg
Application Route	:	Oral
Exposure time	:	30 Days
Target Organs	:	Eye
Symptoms	:	Salivation, Lachrymation, Gastrointestinal disturbance, Liver disorders

Components:

Orbifloxacin:

Species	:	Rat
NOAEL	:	20 mg/kg
LOAEL	:	80 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Testis, Liver, Kidney, spleen

Species	:	Mouse
NOAEL	:	80 mg/kg
LOAEL	:	250 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months

Species	:	Juvenile dog
NOAEL	:	50 mg/kg
LOAEL	:	250 mg/kg
Application Route	:	Oral
Exposure time	:	14 Days
Target Organs	:	Heart, Bone
Symptoms	:	Gastrointestinal disturbance
Remarks	:	mortality observed

Species	:	Juvenile dog
NOAEL	:	2 mg/kg
LOAEL	:	3 mg/kg
Application Route	:	Oral
Exposure time	:	90 Days
Target Organs	:	Bone
Remarks	:	No significant adverse effects were reported

Species	:	Dog
NOAEL	:	37.5 mg/kg

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.0	30.09.2023	785872-00016	Date of first issue: 28.06.2016

Application Route	: Oral
Exposure time	: 30 Days
Species	: Cat
NOAEL	: 7.5 mg/kg
LOAEL	: 22.5 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Symptoms	: Gastrointestinal disturbance

Silicon dioxide:

Species	: Rat
NOAEL	: 1.3 mg/m3
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 13 Weeks

Lactic acid:

Species	: Rat
NOAEL	: > 100 mg/kg
Application Route	: Ingestion
Exposure time	: 13 Weeks
Remarks	: Based on data from similar materials

Species	: Rat
LOAEL	: 886 mg/kg
Application Route	: Skin contact
Exposure time	: 13 Weeks

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Orbifloxacin:

Ingestion	: Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash Remarks: May cause photosensitisation.
-----------	--

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Silicon dioxide:

Toxicity to fish	: LC50 (Danio rerio (zebra fish)): > 10,000 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other	: EC50 (Daphnia magna (Water flea)): > 1,000 mg/l

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.0	30.09.2023	785872-00016	Date of first issue: 28.06.2016

aquatic invertebrates	Exposure time: 24 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Desmodesmus subspicatus (green algae)): > 10,000 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials NOEC (Desmodesmus subspicatus (green algae)): 10,000 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Lactic acid:	
Toxicity to fish	: LC50 (Danio rerio (zebra fish)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: Based on data from similar materials
Toxicity to algae/aquatic plants	: ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials NOEC (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	: EC50: > 10 - 100 mg/l Exposure time: 3 h Method: OECD Test Guideline 209 Remarks: Based on data from similar materials

Persistence and degradability

Components:

Lactic acid:

Biodegradability	: Result: Not readily biodegradable. Remarks: Based on data from similar materials
------------------	---

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.0	30.09.2023	785872-00016	Date of first issue: 28.06.2016

Bioaccumulative potential

Components:

Lactic acid:

Partition coefficient: n-octanol/water : log Pow: -0.62

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.0	30.09.2023	785872-00016	Date of first issue: 28.06.2016

16. OTHER INFORMATION

Revision Date : 30.09.2023

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
IN OEL : India. Permissible levels of certain chemical substances in work environment.

ACGIH / C : Ceiling limit
IN OEL / TWA : Time-Weighted Average Concentration (TWA) (8 hrs.)
IN OEL / CEIL : ceiling limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

SAFETY DATA SHEET

according to the Globally Harmonized System



Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.0	30.09.2023	785872-00016	Date of first issue: 28.06.2016

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN